Aziyo Biologics Inc. is executing growth plans it established ahead of its initial public offering last fall — and starting to see results.
The regenerative medicine firm, which started trading on the Nasdaq in October, saw a first-quarter revenue increase year over year “despite some ongoing Covid-related headwinds,” President and CEO Ron Lloyd said in a statement this week.
{iframe}https://www.bizjournals.com/washington/news/2021/05/07/aziyo-continues-momentum-post-ipo.html{/iframe}